A Phase 1 interventional study of Oral PF-06700841 containing 14C microtracer and Oral unlabeled PF-06700841 in Healthy Male Subjects, sponsored by Pfizer. Completed at 2 sites in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-06.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
An open-label, fixed sequence, 2-period including a single oral dose 60 mg PF-06700841 with 14C-labeled microtracer in 1st period, and a single oral dose of 60 mg unlabeled PF-06700841 followed by intravenous administration of 14C-labeled microdose of PF-06700841 1 hour after oral dose in period 2 to characterize the absorption, disposition, metabolism and excretion of PF-06700841 and evaluate the absolute bioavailability and fraction absorbed in the GI tract
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
fixed sequence with 2 treatment period
Drug: Oral PF-06700841 containing 14C microtracer · Drug: Oral unlabeled PF-06700841 · Drug: IV 14C-labeled PF-06700841
Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
60 mg unlabeled PF-06700841 oral dose in 2nd period
30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period
mass balance_urine
cumulative recovery of radioactivity over time in urine, as percentage of total radioactive dose administered
Time frame: hour 0 up to 312 hours post dose
mass balance_feces
cumulative recovery of radioactivity over time in feces, as percentage of total radioactive dose administered
Time frame: hour 0 up to 312 hours post dose
metabolite identification_plasma
metabolic identification and profiling in plasma following a single oral dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 312 hours post dose
plasma Cmax for total 14C radioactivity
maximum concentration of total 14C radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 312 hours post dose
plasma Tmax for total 14C radioactivity
time with highest concentration of radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 312 hours post dose
plasma AUClast for total 14C radioactivity
area under curve of total 14C radioactivity in plasma from time 0 to tlast following a single oral dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 312 hours post dose
plasma AUCinf for total 14C radioactivity
area under curve of total 14C radioactivity in plasma from time 0 to infinite following a single oral dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 312 hours post dose
Oral clearance for total 14C radioactivity
oral clearance (CL/F) of total activity following a single oral dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 312 hours post dose
plasma half-life for total 14C radioactivity
half-life (t1/2) of total radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 312 hours post dose
volume of distribution for total 14C radioactivity
apparent volume of distribution (Vz/F) of total radioactivity following a single oral dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 312 hours post dose
plasma Cmax for PF-06700841
maximum concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
plasma Tmax for PF-06700841
time with highest concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
plasma AUClast for PF-06700841
area under curve of PF-06700841 in plasma from time 0 to tlast following a single oral dose of 14C-labeled or unlabeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
plasma AUCinf for PF-06700841
area under curve of PF-06700841 in plasma from time 0 to infinite following a single oral dose of 14C-labeled or unlabeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
Oral clearance for PF-06700841
oral clearance (CL/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
plasma half-life for PF-06700841
half-life (t1/2) of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
volume of distribution for PF-06700841
apparent volume of distribution (Vz/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
plasma Cmax for 14C-labeled PF-06700841
maximum concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
plasma Tmax for 14C-labeled PF-06700841
time with highest concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
plasma AUClast for 14C-labeled PF-06700841
area under curve of 14C-labeled PF-06700841 in plasma from time 0 to tlast following a single iv dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
plasma AUCinf for 14C-labeled PF-06700841
area under curve of 14C-PF-06700841 in plasma from time 0 to infinite following a single iv dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
clearance for 14C-labeled PF-06700841
clearance (CL) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
plasma half-life for 14C-labeled PF-06700841
half-life (t1/2) of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
volume of distribution for 14C-labeled PF-06700841
volume of distribution (Vz/F) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 96 hours post dose
unchanged PF-06700841 recovered in urine
percentage of unchanged PF-06700841 recovered in urine (Ae%) following a single oral dose of PF-06700841
Time frame: hour 0 up to 96 hours post dose
renal clearance of PF-06700841
renal clearance (CLr) following a single oral dose of PF-06700841 (Ae%/AUCinf for PF-06700841)
Time frame: hour 0 up to 96 hours post dose
Bioavailability of oral PF-06700841
Absolute bioavailability (F) following a single oral dose relative to a single iv dose of PF-06700841
Time frame: hour 0 up to 96 hours post dose
Fraction absorbed of oral PF-06700841
Fraction absorbed in gut (Fa) following oral dose of PF-06700841
Time frame: hour 0 up to 144 hours post dose
metabolite identification_urine
metabolic identification and profiling in urine following a single oral dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 312 hours post dose
metabolite identification_feces
metabolic identification and profiling in feces following a single oral dose of 14C-labeled PF-06700841
Time frame: hour 0 up to 312 hours post dose
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Dec 2018 to primary completion in Feb 2019, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.